News | August 29, 2014

Direct Flow Medical Gains CE Mark for 23 mm Valve and Implantation Without Use of Contrast

August 29, 2014 — Direct Flow Medical announced it received CE mark for a 23 mm valve as part of its Direct Flow Medical transcatheter aortic valve system, expanding the patient population that can be treated with this technology. The company also announced receipt of the CE mark for implantation of all its valves without the use of contrast media, protecting patients from kidney injury during transcatheter aortic valve implantation (TAVI).

The company now has a valve portfolio that includes 23 mm, 25 mm, 27 mm and 29 mm valves, which can treat patients with annulus sizes from 19 mm to 28 mm. All Direct Flow Medical valves feature a unique, double-ring design that conforms to the anatomy and creates a tight and durable seal around the annulus. The valves allow for complete assessment of hemodynamic performance and unlimited repositioning until optimal results are obtained. All valves can be delivered through the same, low profile and flexible delivery system.

“These approvals are a testament to our continuous focus on innovation and patient outcomes. Physicians will not only be able to treat a broader patient population, but will also be able to implant this technology with no contrast and no compromises,” said Bernard Lyons, CEO of Direct Flow Medical. “Our pipeline of structural heart technologies is strong, and we continue to invest in new products and new indications for our unique therapeutic platform.”

The Direct Flow Medical valve is designed to improve TAVI outcomes by virtually eliminating aortic regurgitation, offering unlimited repositionability during the procedure and reducing overall complications. Acute kidney injury occurs in about 22 percent of patients undergoing TAVI, increasing their risk of peri-procedural complications, prolonged hospitalization and mortality.

“Use of contrast during angiographic procedures is a well-documented cause of acute kidney injury,” said Charles Davidson, M.D., chief medical officer of Direct Flow Medical. “By eliminating or reducing the quantity of contrast administered during TAVI, we will be able to better protect the kidneys and minimize peri-procedural complications.”

The Direct Flow Medical transcatheter aortic valve system is commercially available in Europe. In the United States, the company is progressing towards regulatory approval and is currently enrolling patients in its SALUS pivotal trial.

For more information: www.directflowmedical.com

Related Content

Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge...
New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Overlay Init